Adage Capital Partners Gp, L.L.C. Viridian Therapeutics, Inc.\De Transaction History
Adage Capital Partners Gp, L.L.C.
- $56.4 Billion
- Q2 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 1,108,586 shares of VRDN stock, worth $23.2 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
1,108,586
Previous 1,114,586
0.54%
Holding current value
$23.2 Million
Previous $15 Million
3.15%
% of portfolio
0.03%
Previous 0.03%
Shares
4 transactions
Others Institutions Holding VRDN
# of Institutions
184Shares Held
82.7MCall Options Held
78.9KPut Options Held
417K-
Deep Track Capital, LP Greenwich, CT5.38MShares$112 Million2.67% of portfolio
-
Commodore Capital LP New York, NY4.88MShares$102 Million6.35% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$99.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.51MShares$94.2 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ4.43MShares$92.5 Million7.39% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $833M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...